Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Coenzymes & NAD Precursors

NR (Nicotinamide Riboside)

An NAD+ precursor entering the salvage pathway via NRK1/2, studied in pre-clinical and clinical NAD+ research.

Education Hub

Pre-clinical mechanism

Oral NR is phosphorylated to NMN by NRK enzymes and then converted to NAD+. Animal studies report increases in NAD+ across multiple tissues with associated mitochondrial-biogenesis markers.

Key pre-clinical findings

  • Healthy adults: oral NR raised whole-blood NAD+ in a dose-dependent fashion across an 8-week study (Trammell et al., 2016).

Primary literature

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Trammell SAJ, Schmidt MS, Weidemann BJ, et al. · Nature Communications · 2016

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer